Panitumumab is the first fully human anti-EGFR monoclonal antibody available for the treatment of advanced colorectal cancer. The drug appears to be well tolerated and has demonstrated antitumor activity and clinical benefit both as a single agent and in combination with cytotoxic chemotherapy.
|Original language||English (US)|
|Issue number||10 SUPPL. 4|
|State||Published - Oct 1 2006|
ASJC Scopus subject areas